News & Updates

Treating postnatal depression with selective serotonin reuptake inhibitors (SSRIs) may be beneficial for both mothers and their children in the long term, with a recent study showing that SSRIs can reduce the risk of several negative outcomes, such as maternal depression and child behavioural problems, according to a study.

Atopic dermatitis (AD) is an inflammatory skin disease with complex aetiology and presentation. Globally, AD incidence is heterogeneous – it is higher in Africa and Oceania and lower in India and northeastern and eastern Europe, said Prof Martin Steinhoff, director, Translational Research Institute, Hamad Medical Corporation in Doha, Qatar, who chaired a Pfizer-sponsored symposium during WCD 2023.

AD has a variable course, and its heterogeneous presentation adds complexity to how the disease is managed. The burden of AD is the highest among all skin diseases, added Steinhoff. It has mental health manifestations such as anxiety and depression, chronic itch, fatigue, skin pain, and sleep disturbance. AD may also co-exist with other comorbidities that could impact patients’ general health. “We need to assess every patient carefully and manage them optimally,” he pointed out.

Steinhoff is joined by renowned experts Dr Mahreen Ameen, consultant dermatologist, Royal Free London NHS Foundation Trust, London, UK, and Dr Chih-Ho Hong, dermatologist, Saint Paul Hospital in Vancouver, Canada. Together, they shared four global cases of AD, including treatment options for patients.

Photobiomodulation helps to reduce the severity of chemotherapy-induced peripheral neuropathy (CIPN) and increases mobility in cancer patients as shown in a study presented at EAN 2023.

A higher dose of oral semaglutide than the currently approved 14 mg/day dose may be the next option for overweight or obese patients wanting to lose pounds.

COVID-19 testing has picked up a new coronavirus variant called BA.2.86 – nicknamed Pirola, after an asteroid – in several countries.

Children and adults with atopic dermatitis (AD) are at risk of inflammatory bowel disease (IBD), with the risk varying by age, AD severity, and IBD subtype, according to a study.

Atopic dermatitis (AD) is a chronic relapsing skin disease that requires long-term control. At the 25th World Congress of Dermatology (WCD) in Singapore, Professor Sonja Ständer, professor of dermatology and neurodermatology at the University Hospital Münster, Germany, and Professor Zuotao Zhao, dermatologist from the First Hospital, Peking University, Beijing, China, shared clinical approaches to managing patients with moderate-to-severe AD. The session was chaired by Professor Johannes Ring, director, Department of Dermatology and Allergy, Biederstein at the Technical University of Munich, Germany. Among the key topics discussed were the multifactorial nature of AD, its primary symptoms, and the various therapeutic options for itch relief.